Free Trial
NASDAQ:CLYM

Climb Bio Q3 2024 Earnings Report

Climb Bio logo
$2.38 +0.19 (+8.68%)
As of 08/22/2025 04:00 PM Eastern

Climb Bio EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Climb Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Climb Bio Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Climb Bio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Climb Bio Earnings Headlines

Climb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. Baird
Analysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at Baird R W
What is Leerink Partnrs' Estimate for Climb Bio Q3 Earnings?
See More Climb Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email.

About Climb Bio

Climb Bio (NASDAQ:CLYM) Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

View Climb Bio Profile

More Earnings Resources from MarketBeat